---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-000164"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2024-01-09T23:59:59+00:00"
generated_at: "2026-06-07T01:36:37.962228+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics appoints Bisker-Leib as CEO, Schuetz to President of R&D

## Summary
- Vered Bisker-Leib appointed CEO effective Jan 9, 2024; salary increased to $600k, target bonus 55%.
- Thomas Schuetz transitions from CEO to President of R&D and Vice Chair of Board.
- Bisker-Leib receives options for 1,753,125 shares and RSUs for 1,753,125 shares at $1.93 exercise price.
- Schuetz receives options for 637,500 shares and RSUs for 637,500 shares at $1.93.
- Preliminary unaudited cash, equivalents and marketable securities approx $152M as of Dec 31, 2023.

## SEC filing metadata
- accession: 0001171843-24-000164
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2024-01-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184324000164/0001171843-24-000164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184324000164/f8k_010924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-000164
- JSON: https://secwatch.observer/filing/0001171843-24-000164.json
- Plain text: https://secwatch.observer/filing/0001171843-24-000164.txt

## Key facts
- Executive change
  Vered Bisker-Leib was appointed as Chief Executive Officer at Compass Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”) appointed Vered Bisker-Leib, PhD as Chief Executive Officer of the Company and a member the Board, each effective January 9, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000117184324000164/0001171843-24-000164-index.htm
- Executive change
  Thomas Schuetz changed role as President of Research and Development at Compass Therapeutics, Inc..
  - Action: transitioned
  - Role: President of Research and Development
  source text: Effective January 9, 2024, Thomas Schuetz, MD, PhD, the Company’s Scientific Founder and Chief Executive Officer and a member of the Board, will transition to President of Research and Development and be appointed Vice Chair of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000117184324000164/0001171843-24-000164-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.